The Indian Pharmacopoeia Commission (IPC) issues a drug safety alert concerning the painkiller Meftal, containing mefenamic acid, commonly prescribed for menstrual cramps and arthritis. The alert follows a PvPI database analysis, revealing adverse drug reactions leading to eosinophilia and DRESS syndrome. Healthcare professionals and patients are urged to monitor potential reactions, with a reporting mechanism through the PvPI. The IPC, an autonomous institution under the Ministry of Health, sets standards for drugs in India. The advisory emphasizes vigilance in response to Meftal-related adverse effects.